Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Inclusion Criteria * Patients must have histologically confirmed solid tumors that have failed standard therapies (surgery, chemotherapy, radiotherapy, or endocrine therapy) and for which no curative options exist, including, but not limited to: * Squamous cell carcinoma of the head and neck * Squamous cell carcinoma of the skin * Carcinoma of the breast * Malignant melanoma * Patients may have had any kind and number of prior cancer therapies. * Patients must have measurable non-visceral lesions that are evaluable by the RECIST method * The tumor mass to be treated must be non-visceral and adequate for injection (i.e., more than 2 cm away from major vascular structures) and measurement by RECIST. * Patients in Stage 1 must be seropositive for HSV-1. * The first patient enrolled into each cohort in Stage 2 must be seropositive for HSV-1. * Patients must be ≥ 18 years of age. * Patients must have a life expectancy ≥ 12 weeks * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. * Patients must have adequate hepatic function, as defined as * Total bilirubin levels ≤ 1.5 x upper limit of normal (ULN) * AST/ALT levels ≤ 2.5 x ULN, or ≤ 5 x ULN if liver metastases are present * Patients must have adequate renal function as defined as serum creatinine ≤ 1.5 x ULN or creatinine clearance (calculated) ≥ 60 mL/min/1.73 m2 for patients with creatinine \> 1.5 x ULN * Patients must have adequate bone marrow function, as defined…